NCT05985707尚未招募2 期
The Efficacy and Safety of KN026 Combination Chemotherapy ± KN046 in HER2-Positive Advanced Colorectal Cancer and Biliary Tract Cancer as First-Line Treatment： a Phase Ⅱ Study
Peking University Cancer Hospital & Institute1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2023年8月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Overall response rate
研究概览
简要总结
The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 （a PD-L1/CTLA-4 targeted bispecific antibody）.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants are able to comprehend the informed consent information and sign the informed consent form.
- •Participants ≥ 18 years old, of any gender.
- •Cohorts A and B: Histologically confirmed unresectable HER2-positive metastatic colorectal cancer, meeting the following criteria: a) Previously untreated with systemic anti-tumor therapy, or the time from (neo)adjuvant chemotherapy completion to disease recurrence > 6 months; b) Gene sequencing shows wild-type RAS and BRAF (participants' previous KRAS and BRAF test results are acceptable).
- •Cohort C: Histologically confirmed unresectable HER2-positive biliary tract cancer, including intrahepatic or extrahepatic bile duct cancer or gallbladder cancer: a) Previously untreated with systemic anti-tumor therapy; b) If previously received (neo)adjuvant radiotherapy, the time from treatment completion to disease recurrence is > 6 months.
- •HER-2 positive defined as a) HER2 IHC 3+; b) HER2 IHC 2+ with HER2 amplification (HER2/CEP17 > 2.0 by ISH method)； c) HER copy number > 6 by next-generation sequencing using tumor tissue or circulating tumor DNA.
- •(9) Within 7 days before the first administration, hepatic function should meet the following criteria:
- •Total bilirubin ≤ 1.0 x ULN (≤ 1.5 x ULN for subjects with Gilbert's syndrome or liver metastases)
- •Transaminases (ALT/AST) ≤ 1.5 x ULN (≤ 3 x ULN for subjects with liver metastases) (10) Within 7 days before the first administration, renal function should be as follows:
- •Serum creatinine ≤ 1.5 x ULN
- •Creatinine clearance ≥ 60 mL/min (calculated using the Cockcroft-Gault formula) (11) Within 7 days before the first administration, bone marrow function should meet the following criteria:
- •Hemoglobin ≥ 90 g/L
- •Absolute neutrophil count ≥ 1.5 x 10^9/L
- •Platelet count ≥ 100 x 10^9/L (12) TSH within the normal range; if TSH is abnormal, free T3 and free T4 should be within the normal range.
- •(13) Expected survival of ≥ 3 months. (14) Participants need to receive capecitabine and oxaliplatin regimen chemotherapy based on clinical assessment.
- •(15) Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use effective contraception from 7 days before the first dose until 24 weeks after the last dose. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose.
- •(16) Participants are capable and willing to comply with the study protocol, treatment plan, laboratory tests, and other study-related procedures.
排除标准
- •Subjects with untreated active brain metastases or leptomeningeal metastases; if subjects have received treatment for brain metastases and the lesions are stable (stable brain imaging for at least 4 weeks before the first dose with no evidence of new or enlarging brain lesions and no new neurological symptoms or stable neurological symptoms at baseline), they are allowed to be enrolled.
- •Ampullary carcinoma.
- •Previous history of receiving any systemic anticancer therapy for metastatic tumors or participation in interventional clinical trials.
- •Within 14 days before the first dose, the subject requires a continuous 7-day treatment of systemic corticosteroids (≥10 mg/day prednisone or equivalent of other corticosteroids) or immunosuppressive agents; exceptions are inhaled or locally applied corticosteroids or physiological replacement doses of corticosteroids for adrenal insufficiency. Short-term (≤7 days) corticosteroids are allowed for prevention (e.g., contrast dye allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens).
- •Received live vaccines (including attenuated live vaccines) within 28 days before the first dose.
- •Subjects with interstitial lung disease or requiring oral or intravenous administration of corticosteroids.
- •History or current presence of autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener's granulomatosis (granulomatosis with polyangiitis), Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, autoimmune hepatitis, systemic sclerosis (scleroderma), Hashimoto's thyroiditis (except under certain circumstances as outlined below), autoimmune vasculitis, and autoimmune neurological disorders (such as Guillain-Barre syndrome). The following conditions are exempted: type 1 diabetes, stable hypothyroidism on hormone replacement therapy (including hypothyroidism caused by autoimmune thyroid disease), and psoriasis or vitiligo not requiring systemic treatment.
- •History of another malignant tumor within 5 years before the first dose, except for cured skin squamous cell carcinoma, basal cell carcinoma, non-muscle-invasive bladder cancer, localized low-risk prostate cancer (defined as stage ≤T2a, Gleason score ≤6, and prostate-specific antigen (PSA) ≤10 ng/mL at diagnosis, and patients who received curative treatment without PSA biochemical recurrence), and in situ cervical/breast cancer.
- •Has uncontrolled comorbidities, including but not limited to the following conditions:
- •Active HBV or HCV infection.
- •Subjects with positive HBsAg and/or HCV antibodies during screening must undergo HBV DNA and/or HCV RNA testing. Subjects with HBV DNA ≤ 500 IU/mL (or ≤ 2000 copies/mL) and/or HCV RNA negative can be enrolled; during the trial, the investigator will decide on monitoring HBV DNA based on the subject's situation.
- •Known HIV infection or history of AIDS.
- •Active tuberculosis.
- •Active infection or systemic use of antimicrobial drugs for more than 1 week within 28 days before the first dose of this study; unexplained fever within 2 weeks before dosing.
- •Uncontrolled hypertension (resting blood pressure ≥ 160/100 mmHg), symptomatic heart failure (NYHA class II-IV), unstable angina or myocardial infarction within the past 6 months, or risk of QTc prolongation or arrhythmia (baseline QTc > 470 msec corrected by Fridericia method, difficult-to-correct hypokalemia, long QT syndrome, resting heart rate > 100 bpm with atrial fibrillation, or severe valvular heart disease).
- •Active bleeding that cannot be controlled even with medical intervention.
- •History of allogeneic bone marrow or organ transplantation.
- •History of allergic reactions, hypersensitivity, or intolerance to antibody-based drugs; history of significant drug allergies (e.g., severe allergic reactions, immune-mediated hepatotoxicity, immune-mediated thrombocytopenia, or anemia).
- •Pregnant and/or lactating females.
- •Other conditions that, in the opinion of the investigator, may affect the safety or compliance of the study drug treatment, including but not limited to moderate to large pleural/peritoneal/pericardial effusion, difficult-to-correct pleural/peritoneal/pericardial effusion, intestinal obstruction or subacute intestinal obstruction, psychiatric disorders, etc.
研究组 & 干预措施
A
Experimental
Arm A will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 treatment.
干预措施: KN026 (Drug)
A
Experimental
Arm A will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 treatment.
干预措施: XELOX (Drug)
B
Experimental
Arm B will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
干预措施: KN026 (Drug)
B
Experimental
Arm B will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
干预措施: KN046 (Drug)
B
Experimental
Arm B will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
干预措施: XELOX (Drug)
C
Experimental
Arm C will include HER2-positive treatment-naive metastatic biliary tract cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
干预措施: KN026 (Drug)
C
Experimental
Arm C will include HER2-positive treatment-naive metastatic biliary tract cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
干预措施: KN046 (Drug)
C
Experimental
Arm C will include HER2-positive treatment-naive metastatic biliary tract cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
干预措施: XELOX (Drug)
结局指标
主要结局
Overall response rate
时间窗: Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 24 months post-dose
Objective response rate (defined as CR+PR) is reported based on investigator's evaluation.
次要结局
- Time to response(Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 24 months post-dose)
- Duration of response(Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 24 months post-dose)
- Disease control rate(Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 24 months post-dose)
- Frequency of adverse events(From the date of signing the informed consent form up to 30 (+7) days after last dose.)
- Progression free survival(Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 24 months post-dose)
- Overall survival(Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 24 months post-dose)
研究者
Shen Lin
Professor
Peking University Cancer Hospital & Institute
研究点 (1)
Loading locations...
相似试验
已完成
2 期
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)ObesityNCT00109148Merck Sharp & Dohme LLC500
已完成
1 期
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerTriple-negative Breast CancerNCT03872791Jiangsu Alphamab Biopharmaceuticals Co., Ltd52
Unknown
2 期
Study of KN046 With Chemotherapy in First Line Advanced NSCLCNon-small Cell Lung CancerNCT04054531Jiangsu Alphamab Biopharmaceuticals Co., Ltd50
招募中
不适用
Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing TrialGastric CancerNCT05952375The Affiliated Hospital of Qingdao University9
已完成
1 期
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT00077883Telik50